Mylan Continues Slide As Generic Price Slowdown Hits Results, Outlook
August 09, 2017 at 15:03 PM EDT
Shares of Mylan are sliding after the company reported worse than expected earnings for the quarter and cut its financial outlook for 2017 and 2018, citing a price slowdown in generic drugs.